全文获取类型
收费全文 | 3121篇 |
免费 | 210篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 78篇 |
妇产科学 | 59篇 |
基础医学 | 362篇 |
口腔科学 | 203篇 |
临床医学 | 449篇 |
内科学 | 910篇 |
皮肤病学 | 45篇 |
神经病学 | 145篇 |
特种医学 | 100篇 |
外国民族医学 | 4篇 |
外科学 | 338篇 |
综合类 | 41篇 |
一般理论 | 5篇 |
预防医学 | 277篇 |
眼科学 | 25篇 |
药学 | 104篇 |
肿瘤学 | 157篇 |
出版年
2021年 | 41篇 |
2020年 | 23篇 |
2019年 | 50篇 |
2018年 | 56篇 |
2017年 | 38篇 |
2016年 | 46篇 |
2015年 | 53篇 |
2014年 | 64篇 |
2013年 | 85篇 |
2012年 | 141篇 |
2011年 | 156篇 |
2010年 | 95篇 |
2009年 | 89篇 |
2008年 | 150篇 |
2007年 | 183篇 |
2006年 | 161篇 |
2005年 | 155篇 |
2004年 | 140篇 |
2003年 | 121篇 |
2002年 | 118篇 |
2001年 | 78篇 |
2000年 | 81篇 |
1999年 | 75篇 |
1998年 | 36篇 |
1997年 | 27篇 |
1996年 | 25篇 |
1995年 | 26篇 |
1994年 | 20篇 |
1992年 | 79篇 |
1991年 | 54篇 |
1990年 | 68篇 |
1989年 | 51篇 |
1988年 | 51篇 |
1987年 | 63篇 |
1986年 | 41篇 |
1985年 | 54篇 |
1984年 | 41篇 |
1983年 | 49篇 |
1982年 | 23篇 |
1980年 | 28篇 |
1979年 | 31篇 |
1978年 | 29篇 |
1977年 | 33篇 |
1976年 | 22篇 |
1975年 | 24篇 |
1974年 | 25篇 |
1973年 | 18篇 |
1972年 | 25篇 |
1971年 | 28篇 |
1970年 | 22篇 |
排序方式: 共有3345条查询结果,搜索用时 15 毫秒
51.
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma 下载免费PDF全文
52.
Gennady Bratslavsky Stephanie Gleicher Joseph M. Jacob Thomas H. Sanford Oleg Shapiro Dimitra Bourboulia Laurie M Gay Julie Andrea Elvin Jo-Anne Vergilio James Suh Shakti Ramkissoon Eric Allan Severson Jonathan Keith Killian Alexa Betzig Schrock Jon H. Chung Vincent A. Miller Mehdi Mollapour Jeffrey S. Ross 《Urologic oncology》2021,39(6):367.e1-367.e5
Introduction and ObjectiveUnlike clear cell renal cell carcinoma (CCRCC), collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are rare tumors that progress rapidly and appear resistant to current systemic therapies. We queried comprehensive genomic profiling to uncover opportunities for targeted therapy and immunotherapy.Material and MethodsDNA was extracted from 40 microns of formalin-fixed, paraffin-embedded specimen from relapsed, mCDC (n = 46), mRMC (n = 24), and refractory and metastatic (m) mCCRCC (n = 626). Comprehensive genomic profiling was performed, and Tumor mutational burden (TMB) and microsatellite instability (MSI) were calculated. We analyzed all classes of genomic alterations.ResultsmCDC had 1.7 versus 2.7 genomic alterations/tumor in mCCRCC ( = 0.04). Mutations in VHL (P < 0.0001) and TSC1 (P = 0.04) were more frequent in mCCRCC. SMARCB1 (P < 0.0001), NF2 (P = 0.0007), RB1 (P = 0.02) and RET (P = 0.0003) alterations were more frequent in mCDC versus mCCRCC. No VHL alterations in mRMC and mCDC were identified. SMARCB1 genomic alterations were significantly more frequent in mRMC than mCDC (P = 0.0002), but were the most common alterations in both subtypes. Mutations to EGFR, RET, NF2, and TSC2 were more frequently identified in mCDC versus mRMC. The median TMB and MSI-High status was low with <1% of mCCRC, mCDC, and mRMC having ≥ 20 mut/Mb.ConclusionGenomic alteration patterns in mCDC and mRMC differ significantly from mCCRCC. Targeted therapies for mCDC and mRMC appear limited with rare opportunities to target alterations in receptor tyrosine kinase and MTOR pathways. Similarly, TMB and absence of MSI-High status in mCDC and mRMC suggest resistance to immunotherapies. 相似文献
53.
54.
Carl M. Gay C. Allison Stewart Elizabeth M. Park Lixia Diao Sarah M. Groves Simon Heeke Barzin Y. Nabet Junya Fujimoto Luisa M. Solis Wei Lu Yuanxin Xi Robert J. Cardnell Qi Wang Giulia Fabbri Kasey R. Cargill Natalie I. Vokes Kavya Ramkumar Bingnan Zhang Lauren Averett Byers 《Cancer cell》2021,39(3):346-360.e7
55.
Gemma Mayor-Subirana José Yagüe-García Eduard Valmaseda-Castellón Josep Arnabat-Domínguez Leonardo Berini-Aytés Cosme Gay-Escoda 《Medicina oral, patología oral y cirugía bucal》2014,19(2):e192-e201
Objectives: To evaluate the efficacy of Oraqix® during scaling and root planing (SRP) in comparison with 20% benzocaine and placebo.
Study Design: 15 patients requiring 4 sessions of SRP were enrolled. For each patient, Oraqix®, Hurricaine®, vaseline or no anesthetic product were randomly assigned each to a quadrant. Treatment pain was evaluated on a 100 mm Visual Analog Scale (VAS) and on a Verbal Rating Scale (VRS). The amount of product administered, the need to re-anesthetise, patient and operator satisfaction and the onset of side-effects were also recorded.
Results: Oraqix® was significantly better than nothing, with a reduction of VAS score to 13.3 units, but without significant differences with Vaseline or Hurricaine®. Oraqix® was better in VRS reduction than not using any anesthetic (p=0.001) or using vaseline (p=0.024), but similar to Hurricaine® (p=0.232).
Conclusions: Oraqix® effectively controls pain in SRP procedures, with few side-effects and a good acceptance on the part of patients and clinicians.
Key words:Controlled clinical trial, topical anesthetic, scaling and root planing. 相似文献
56.
57.
58.
59.
Do governing body and CSU nurses on clinical commissioning groups really lead a nursing agenda? Findings from a 2015 Survey of the Commissioning Nurse Leaders' Network Membership 下载免费PDF全文